Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction - sprookjes - yvandenbroek - TriplyDB

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

http://www.wikidata.org/entity/Q29618673

about

Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - Summary Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology:Fibrates for type 2 diabetes mellitus Percutaneous coronary intervention versus coronary artery bypass grafting for adults with diabetes and multivessel coronary disease Colesevelam for type 2 diabetes mellitus Adenosine-diphosphate (ADP) receptor antagonists for the prevention of cardiovascular disease in type 2 diabetes mellitus Fibrates for type 2 diabetes mellitus Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus Rosiglitazone for type 2 diabetes mellitus Pioglitazone for type 2 diabetes mellitus Adenosin-diphosphate (ADP) receptor antagonists (clopidogrel, ticlopidine) for the prevention of cardiovascular disease in type 2 diabetes mellitus Activin A impairs insulin action in cardiomyocytes via up-regulation of miR-143 Reduced expression of ATP-binding cassette transporter G1 increases cholesterol accumulation in macrophages of patients with type 2 diabetes mellitus Comparing coronary artery bypass grafting with drug-eluting stenting in patients with diabetes mellitus and multivessel coronary artery disease: a meta-analysis The associations of cholesterol metabolism and plasma plant sterols with all-cause and cardiovascular mortality Plant sterols and cardiovascular disease: a systematic review and meta-analysis Diabetes surgery: a new approach to an old disease Concentrations of urinary phthalate metabolites are associated with increased waist circumference and insulin resistance in adult U.S. males Risk factors in coronary atherosclerosis athero-inflammation: the meeting point Clinical significance of cardiovascular dysmetabolic syndrome Cardiovascular adaptations to exercise training in postmenopausal women with type 2 diabetes mellitus The "Statinth" wonder of the world: a panacea for all illnesses or a bubble about to burst.Variation in diabetes care by age: opportunities for customization of care Influence of diabetes mellitus on heart failure risk and outcome Disparities in lipid management for African Americans and Caucasians with coronary artery disease: a national cross-sectional study Prevalence of antiplatelet therapy in patients with diabetes.Percutaneous coronary intervention versus coronary artery bypass grafting for adults with diabetes and multivessel coronary disease The Role of Hyperglycemia and Insulin Resistance in the Development and Progression of Pulmonary Arterial Hypertension 2015 Korean Guidelines for the Management of Dyslipidemia: Executive Summary (English Translation)Diabetes Dyslipidemia Prescription omega-3 fatty acid products: considerations for patients with diabetes mellitus Pancreatic regulation of glucose homeostasis Aspirin for primary prevention of cardiovascular disease High-Risk Cardiovascular Patients: Clinical Features, Comorbidities, and Interconnecting Mechanisms Sodium-Glucose Cotransporter 2 Inhibitors: Possible Anti-Atherosclerotic Effects Beyond Glucose Lowering Diabetic Cardiovascular Disease Induced by Oxidative Stress Subclinical Hypothyroidism and Type 2 Diabetes: A Systematic Review and Meta-Analysis Peripheral artery disease in patients with diabetes: Epidemiology, mechanisms, and outcomes Cardiovascular effects of glucagon-like peptide 1 (GLP-1) receptor agonists

P2860

Q21246041-65DBD6BF-6152-49FB-BB34-745D428ED36C Q22241786-EAAA1ABF-ED65-4D21-BEF7-0D9E6690109E Q22242896-C2DF549D-BC37-4431-8BAD-0513E93051DB Q24195161-BC778C31-CE63-4A24-88B6-77AFEEE93F52 Q24198875-C73A8174-EE3C-4EF3-BEE4-97C41F8F0E2B Q24202334-010E1C1E-31A5-4CA3-8A9F-A17FD3A80967 Q24203035-AC87A6CC-EC36-4F19-AD88-E7D6DD54670C Q24204016-6A0FF8F5-6054-4D13-A3E3-184E92AE3EC2 Q24243196-D4F9DA41-5161-42F4-A40C-6DE0BD61F3FD Q24243875-F3C815C4-6280-4543-AC27-87E885F06A74 Q24244321-04D723A1-C11A-4BE2-9C2E-FDE537D34947 Q24246789-E1C5B3B7-B294-490B-B7AE-3D3763F7320C Q24297012-C0A6024D-CF70-471E-99FF-C14AA0C838D6 Q24314471-F8166AF4-B6A5-4D82-A31A-732881394350 Q24603109-3171DF53-6720-449F-A2D3-C48F900523D1 Q24609527-E8EA9C42-03BA-4C97-B4A2-BF56C147ACF5 Q24632486-F35D5910-6490-45F4-8E1F-7928DC8D3FB2 Q24657676-18BBA1E9-8FB3-4BA5-942D-1BAF4CCE999D Q24672743-75312799-661F-4045-98AB-5234AB9F405A Q24793107-AE9C46DA-6BA4-49CE-B575-98301C331D16 Q24794239-2EA4A658-6EBF-4024-9B50-9D3C7753FFDE Q24795836-DE6CA237-AC5A-4872-8644-CF6914AC5FD0 Q24796000-9D3364FC-21AF-4747-B7F9-670578D60608 Q24797542-6CC9AB8C-1CA2-4447-BD61-317D8E62B4C8 Q24800363-1BE6F2EB-7B5C-465F-8522-B60AC53E0C56 Q24805660-E4B4051D-498E-40C0-9A50-33BB83DF016A Q24813940-C1810E56-50D0-4265-8222-30FCC87DA1D8 Q26471346-2C4DB6CE-DE60-4AE0-A71E-11DE4F99AC0D Q26744761-93B96F2D-DA8E-4163-A249-F8EDFACE3E52 Q26747559-4A13572B-CBF5-4643-85F0-46B752EFFABE Q26750905-8ED2ED5F-E923-4F2E-A1B5-48B870756097 Q26752919-366E0FF6-0EEE-457D-BACF-85DFCC8C392E Q26766485-4E1266B5-965D-4824-AEE4-AD7D818B8B2F Q26774150-6E4B0157-6EA0-47C2-8DD2-7DF7169C0B49 Q26774658-7303A676-7817-4EBD-8233-69E729A34BC2 Q26775823-B3A28E04-A58B-4387-8620-6B04BA29518F Q26778017-7AE55DC4-65CF-4596-98A6-76886068B697 Q26798245-1EE5E34E-4076-43CC-ABA7-97F2BB6B9E05 Q26799591-394DF87E-1141-4996-964C-DFF502C95699 Q26823085-4282BB07-60EC-45CF-8D78-D0BFD1EA3E38

P2860

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

http://www.wikidata.org/entity/Q29618673

description

1998 nî lūn-bûn

@nan

1998 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

1998 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

1998年の論文

@ja

1998年論文

@yue

1998年論文

@zh-hant

1998年論文

@zh-hk

1998年論文

@zh-mo

1998年論文

@zh-tw

1998年论文

@wuu

name

Mortality from coronary heart ...... ut prior myocardial infarction

@ast

Mortality from coronary heart ...... ut prior myocardial infarction

@en

type

label

Mortality from coronary heart ...... ut prior myocardial infarction

@ast

Mortality from coronary heart ...... ut prior myocardial infarction

@en

altLabel

Mortality from Coronary Heart ...... ut Prior Myocardial Infarction

@en

prefLabel

Mortality from coronary heart ...... ut prior myocardial infarction

@ast

Mortality from coronary heart ...... ut prior myocardial infarction

@en

P1433

Q29618673-5626CC7E-49B0-498D-9C5C-668956EE6B5B

P1476

Q29618673-43DCC706-D57B-40C8-A8E5-F6251964A804

P2093

Q29618673-442B28DB-9849-4238-96C1-83F0B3EA5ECF

Q29618673-9ADE74FA-E594-4660-B86D-16B3D655518A

Q29618673-ACA3BED1-287F-4270-B69B-867803AC3A36

Q29618673-F2E99BC6-3B8A-4829-BC6E-34213622B8AC

P304

Q29618673-14B927C6-5181-402E-830D-44D82C8B1521

P31

Q29618673-E97E946D-D1AC-4EE3-B32B-16B32F18A60C

P3181

Q29618673-BEC719EE-C377-46F0-9D49-B5BF40225F40

P356

Q29618673-CD1D86C5-3639-4520-AF84-DB831D1D8C55

P407

Q29618673-27D6871C-D62F-44E9-82F7-268136C5FF16

P433

Q29618673-2F23C1DE-0BE3-4884-9AE8-DCE0D4555FFC

P478

Q29618673-4E7D55E7-2FD3-412C-BEB2-ABB57120672B

P50

Q29618673-511915E6-082F-4F7D-B07B-DCEA9DC57527

P577

Q29618673-C23E996D-EE48-4897-B01B-A8BE65A90D0E

P698

Q29618673-8367425C-CA9E-4F28-B5EB-DBEAA91EAFF0

P921

Q29618673-3F0C7B1C-0F10-4149-8DCF-D34336A00963

Q29618673-E0EF881C-940F-4AF9-954F-2FAFAC0DEB33

P3181

P356

NEJM199807233390404

P1433

The New England Journal of Medicine

P1476

Mortality from coronary heart ...... ut prior myocardial infarction

@en

P2093

Haffner SM

http://www.w3.org/2001/XMLSchema#string

Lehto S

http://www.w3.org/2001/XMLSchema#string

Pyörälä K

http://www.w3.org/2001/XMLSchema#string

Rönnemaa T

http://www.w3.org/2001/XMLSchema#string

P304

229-34

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

46503

http://www.w3.org/2001/XMLSchema#string

P356

10.1056/NEJM199807233390404

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

339

http://www.w3.org/2001/XMLSchema#string

P50

P577

1998-07-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

9673301

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes